Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Conbercept for diabetic macular edema in real-world practice in China
ChiCTR2200064404Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of conbercept in diabetic macular edema (DME), sponsored by Shanghai General Hospital. Primary endpoint: best corrected visual acuity. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2200064404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064404.